Sarcopenia Linked to Smoking in Osteoarthritis

Save

Sarcopenia commonly has been linked to aging and arthritis and contributes significantly to quality of life and outcomes, but the association between sarcopenia and OA has not been well established.

Biomarker Predicts Survival in Autoimmune Lung Disease

Save

One major subgroup of patients with interstitial lung disease (ILD) arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found.

Best of 2023: Treatment and Management of Neuropsychiatric Lupus

Save

At the 2023 ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Save

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

StillsNow Podcast December 2023 - ACR23 Highlights

Save

Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.

Best of 2023: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions

Save

The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

Save

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to halt disease progression and prevent life-threatening complications from HLH/MAS.

Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Save

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).

Best of 2023: New Laboratory Insights for the ANA+ Consult

Save

A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).

Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease

Save

The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.

Best of 2023: How Being a Patient Taught Me to Be a Better Doctor

Save

When I was accepted into medical school, my Dad (a trauma surgeon) taught me that as a doctor I should not judge and do my best not to let my personal views interfere with how I manage and interact with my patients.

Best of 2023: LAVLI - A New Autoinflammatory Disorder

Save

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic inflammation, by altering microvascular permeability and neutrophil recruitment, while at the same time promoting hepatic fibrosis.